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habitat overlaps with that of pteropid 
bats in southern Vietnam.
Previous studies showed that 
IgG ELISA results for NiV-positive 
fl ying foxes correlated well with NT 
results (3,4). However, in our study, 
discrepancies existed between NT 
results and NiV-N-ELISA and WB 
results. A reason for these differences 
could be that Nipah-like viruses are 
circulating among bats in Vietnam, 
producing antibodies that are cross-
reactive by ELISA and WB, but poorly 
cross-reactive by NT. The cross-
reactive antibodies were probably not 
directed against neutralizing epitopes. 
To date, no reports have been made 
of an increased number of febrile 
encephalitis cases among the residents 
in Hoa Binh and Dak Lak Provinces 
where seropositive bats were captured. 
The circulating viruses may lack the 
pathogenic potential of Hendra and 
Nipah viruses.
A survey by questionnaire was 
conducted among residents of Dak 
Nong and Dak Lak Provinces, where 
NiV-N-ELISA–positive C. sphinx 
bats were captured, to determine the 
frequency of contact between humans 
and bats. Risk factors for infection 
were observed in this study, such as bat 
hunting and cooking and drinking bat 
blood. In such situations, persons have 
direct contact with bat body fl uids and 
feces and might be bitten during bat 
hunting. Thus, long-term systematic 
surveillance of bats is needed to 
determine the ecologic relationship 
between bats, humans, other animals, 
and the environment.
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To the Editor: Multidrug-
resistant tuberculosis (MDR TB), 
i.e., TB resistant to at least the 2 most 
effective fi rst-line antituberculous 
drugs (isoniazid [INH] and rifampin 
[RIF]), is increasing globally. World 
Health Organization estimations of 
390,000–510,000 new MDR TB cases 
and 150,000 related deaths in 2008 
highlight the need for timely drug 
susceptibility testing and improved 
therapies (1). Although novel rapid 
drug susceptibility testing tools are 
increasingly available, their clinical 
applicability is unsettled. We report 
a patient with pulmonary TB relapse 
with discordant genotypic and in vitro 
phenotypic drug susceptibility testing 
results associated with a mutation 
outside the RIF resistance determining 
region (RRDR) of the rpoB gene.
In August 2009, a 45-year-old 
homeless woman with AIDS (CD4+ 
T-cell count 3 cells/mm3) and a history 
of substance abuse sought care for 
fever, night sweats, weight loss, 
and cough (online Appendix Table, 
wwwnc.cdc.gov/EID/article/18/3/11-
1357-TA1.htm). Pulmonary TB had 
been diagnosed in June 2008. At 
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that time, she received, by directly 
observed therapy, 6 weeks of INH, 
RIF, pyrazinamide (PZA), and 
ethambutol (EMB) through the local 
health department and was switched to 
RIF, PZA, and EMB on week 7 after 
the isolate was determined by liquid 
culture with BD BACTEC MGIT 960 
Mycobacterial Testing System (BD 
Diagnostics, Sparks, MD, USA) to be 
INH resistant. During that period, she 
resided in American Lung Association–
supported housing for TB patients and 
had 97% medication adherence by 
dose count. Her condition clinically 
improved, infi ltrates completely 
resolved according to chest radiograph, 
12 sputum inductions failed to yield 
suffi cient material for analysis, and 
she began highly active antiretroviral 
therapy (HAART). In December 2008, 
however, because of crack cocaine 
use and belligerent behavior, she lost 
housing privileges. Caseworkers could 
not locate her to complete the 9-month 
planned directly observed therapy.
The woman was hospitalized in 
January and again in February 2009 
with dyspnea and off medications. 
In both instances, chest radiographs 
showed no new changes, sputum 
specimens were negative for acid-
fast bacilli (AFB) by microscopy 
and culture, and she was treated for 
presumptive Pneumocystis pneumonia 
and showed clinical improvement.
In August 2009, she was 
readmitted with cough and new 
cavitation on chest radiograph. 
Chest computed tomographic scan 
demonstrated right upper lobe 
infi ltrates, bilateral lower lobe 
cavitation, and hilar and mediastinal 
lymphadenopathy. Sputum AFB 
smear was positive (graded 4+), and 
nucleic acid amplifi cation (Amplifi ed 
Mycobacterium Direct Test; Gen-
Probe, San Diego, CA, USA) 
was positive for Mycobacterium 
tuberculosis complex. INH, RIF, 
PZA, and EMB, along with 
moxifl oxacin (MXF) and amikacin 
(AMK), were initiated in accordance 
with 2003 national TB treatment 
guidelines for possible MDR TB (2). 
Shortly thereafter, a line probe assay 
(GenoType MTBDRplus; HAIN 
Lifescience, Nehren, Germany) 
performed by Southeastern National 
TB Center (Gainesville, FL, USA) on 
the culture of the sputum specimen 
obtained at admission indicated an 
inhA point mutation but no mutation 
in the RRDR region of the rpoB gene, 
which suggested that the isolate was 
INH resistant but RIF susceptible. 
AMK was discontinued, and the 
patient was discharged with RIF, PZA, 
EMB, and MXF.
One week later, drug sus-
ceptibility testing (BD BACTEC 
MGIT 960 System) results from the 
state mycobacteriology laboratory 
demonstrated that the M. tuberculosis 
isolate was resistant to INH and 
RIF. The patient was readmitted to 
resume injectable aminoglycoside 
therapy. After 5 weeks, sputum 
culture became negative, clinical 
and radiographic improvement was 
apparent, and HAART was reinitiated. 
She completed 2 months’ INH/PZA/
EMB/MXF/AMK inpatient therapy 
and was discharged to complete 6 
additional months of PZA/EMB/
MXF and streptomycin followed by 
16 months of PZA/EMB/MFX. With 
HAART, her plasma HIV RNA viral 
load became undetectable, but her 
CD4 count remained low (9 cells/
mm3). She died from a motor vehicle 
accident 10 months after recurrent TB 
was diagnosed.
In this patient, RIF resistance 
was not predicted by line probe assay 
but was identifi ed phenotypically by 
an automated system (BD BACTEC 
MGIT 960 System) that continuously 
monitors for growth and detection of 
mycobacteria. Through genotyping 
and DNA sequencing of the 2008 
and 2009 M. tuberculosis isolates, 
the Mycobacteriology Laboratory 
Branch at the Centers for Disease 
Control and Prevention (Atlanta, 
GA, USA) established that the 2009 
infection was a relapse, not re-
infection, and confi rmed the inhA 
mutation in both isolates. Using 
primers extending beyond the RRDR 
(the rpoB region surveyed by rapid 
molecular tests and responsible for 
>95% of RIF resistance mutations) 
the laboratory identifi ed a novel 
rpoB gene mutation at codon 480 
(ACC→AAC; Thr→Asn) and 
another previously described (3–5) 
mutation at codon 176 (GTC→TTC; 
Val→Phe) in the 2009 isolate, which 
has been implicated in RIF resistance. 
The role of the T480N mutation in 
RIF resistance is being investigated.
This case demonstrates the 
limitations of rapid molecular drug 
susceptibility testing (6). Rapid 
molecular diagnostics are valuable 
adjuncts to conventional phenotypic 
testing because they can quickly 
confi rm clinically suspected MDR TB 
and have high agreement with other 
genotypic and phenotypic methods 
(7–10). However, they should not 
supplant phenotypic testing, and 
clinicians should understand their 
limitations. When rapid molecular 
tests are negative but suspicion for 
MDR TB is high, MDR TB treatment 
should be continued until phenotypic 
susceptibility results are available. 
DNA sequencing may be best suited for 
evaluating suspected drug-resistant M. 
tuberculosis isolates with discordant 
results for phenotypic susceptibility 
and rapid molecular testing.
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High Incidence of 
Group B 
Streptococcal 
Infection in Infants 
Born to HIV-
Infected Mothers
To the Editor: In their cross-
sectional study comparing group B 
streptococcus (GBS) carriage among 
HIV-infected and HIV-uninfected 
women in Malawi, Gray et al. found 
no differences in GBS carriage 
between both groups but found a 
higher carriage rate for HIV-infected 
women with high CD4 cell counts 
(1). They proposed that a GBS-
specifi c immune defect might exist 
in HIV-infected pregnant women and 
suggested that this defect could be 
blurred by competitive exclusion of 
GBS as a consequence of changes in 
microbial fl ora at lower CD4 counts.
We recently reported an increased 
incidence of neonatal GBS sepsis 
in HIV-exposed uninfected (HEU) 
infants born in Belgium, compared 
with the general population (2). In 
our cohort, the risk for GBS infection 
was 20× higher in HEU infants than 
in infants born to HIV-uninfected 
mothers. Moreover, the episodes of 
GBS sepsis in HEU infants, compared 
with the general population, were 
more severe and mostly of late onset. 
We are currently looking prospectively 
at GBS carriage in HIV-infected and 
control uninfected pregnant women to 
learn whether our observation can be 
explained by a higher carriage rate in 
HIV-infected women or by increased 
susceptibility of HEU infants to 
this capsulated bacteria. The latter 
hypothesis would be in line with the 
higher susceptibility of HEU children 
to other types of severe infections, as 
has been described in several studies 
from sub-Saharan Africa and Latin 
America (3–5).
The incidence of GBS sepsis in 
HIV-exposed infants born in Africa 
is unknown. In addition to the need 
for further investigation of anti-GBS 
immunity in HIV-infected pregnant 
women, we believe that studies 
comparing the incidence of neonatal 
GBS sepsis in HEU and HIV-unexposed 
infants are warranted. If the increased 
risk for GBS sepsis is confi rmed, 
prophylaxis should be implemented in 
the population concerned.
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